

EUROGIN 2011

**HPV Associated Diseases and Cancer
 From Reality now to the Future**

Lisbon (Portugal) – May 8-11, 2011

PRELIMINARY PROGRAM

HONORARY PRESIDENTS:

T. Cox (USA) – J. Cuzick (UK) – C. De Oliveira (Portugal)

Chairman of the Scientific Committee:

J. Monsonego (France)

TRAINING COURSE

**The broad spectrum of HPV associated diseases:
 from science to practice**

Sunday, May 8, 2011

The training course is designed to provide summaries of the most relevant knowledge on HPV infection and associated diseases with the aim of assisting physicians and educators in their practice. The topics cover a broad range from basic science fundamentals to emerging topics on HPV associated diseases in various locations, as well as the clinical uses of screening technologies, prophylactic HPV vaccines and management issues.

Speakers will present only accepted evidence-based scientific information that has been published in the peer-reviewed medical literature.

Sunday, May 8

TC1 HPV infection and associated diseases in the lower genital tract (cervix – vagina - vulva)

8:15 – 10:00 TC1-1 Basic research and fundamentals: state of the art

Chair: X. Bosch, J. Doorbar

- | | | |
|---|---------------|-------|
| • Pathogenesis and molecular biology | J. Doorbar | UK |
| • Burden of HPV associated precancers and cancers | J. Smith | USA |
| • Epidemiology of HPV infection | X. Bosch | Spain |
| • Natural history revisited: age specific relationship and implications for clinical practice | N. Wentzensen | USA |

- Chromosomal profiling of high-grade CIN arising from prevalent versus incident hrHPV infections P.Snijders

The Netherlands

- Discussion

10:00 –
10:30

Coffee break

10:30 –
12:30

TC1-2 Screening and vaccination – current knowledge and perspectives

Chair: J. Cuzick, J. Schiller

- Cytology based screening A. Herbert UK
- The clinical value of molecular testing in primary screening T. Wright USA
- Implementation of guidelines for cervical cancer screening A. Anttila Finland
- Prophylactic vaccines update J. Schiller USA
- Vaccination programs: current experience and improvements P. L. Lopalco Sweden
- Integrating vaccination and screening M. Saraiya USA
- Discussion

14:00 –
15:30

TC1-3 Management procedures of cervical HPV associated diseases – the standards revisited – accuracy and limitations

Chair: T. Cox, M. Stoler

- Performance of colposcopy R. Pretorius USA
- The role of HPV testing for management of abnormal pap J. Roelens Belgium
- New evidences for an accurate follow-up T. Cox USA
- How to treat safely high grade CIN W. Prendiville Ireland
- Impact of HPV vaccines on disease and management E. Joura Austria
- Discussion

15:30 – 16:00 **Coffee break**

TC2 HPV related neoplasia and cancer in anus, external genitalia and head & neck – facts and figures

16:00 – 17:30

Chair: A. Giuliano, H. Mehanna

- Vulvar HPV related lesions: current knowledge M. Sideri Italy
- Anal neoplasia: epidemiology, diagnostics and prevention J. Palefsky USA
- Penile HPV associated diseases: what the clinician should know A. Giuliano USA
- The burden of head & neck HPV related cancers and the potential impact of HPV vaccines M. Gillison USA
- Head and neck cancer: the significance of HPV infection and treatment issues H. Mehanna UK
- Discussion

Sunday, May 8

FC1 Epidemiology 1

10:30 – 12:30 Chair : K. Syrjänen, A. Morais, F. Borruto

Sunday, May 8

FC2 Epidemiology 2

14:00 – 15:30 Chair : M. Steben, K. Irwin, P. Sparen

Sunday, May 8

FC3 Cytology and screening

15:30 – 17:00 Chair : H. Ikenberg, H. Kaufmann

Sunday, May 8

FC4 HPV testing

10:30 – 12:30 Chair: P. Halfon, C. Mouglin

Sunday May, 8

FC5

HPV testing methods

Chair: C. Clavel, P. Snijders, JL Prétet

14:00 – 16:15

Sunday May, 8

FC6

Molecular markers

Chair: P. Hillemanns, F. Mota

16:15 – 17:30

Sunday, May 8

EUROGIN – WACC SESSION

14:00 – 16:30

Programs, knowledge, awareness and education

Chair: D. Harper, M. Pitts, A. Szarewski

Plenary Sessions (PS)

Plenary Sessions will include keynote lectures providing a broad overview of the essential issues of cervical cancer prevention by the most prominent experts in their respective field.

Clinical (translational) sessions (CS): from basic science to clinical practice

Debates on controversial issues

The clinical sessions are designed to provide educational strategies and skill-building learning experiences and update of expertise for participants. The clinical sessions should enable participants to integrate in their everyday practice the basic and advanced principles of colposcopy as well as diagnosis and management of cervico-vaginal and vulvar diseases.

Concurrent Scientific Sessions (SS)

These concurrent sessions feature presentations of selected abstracts on new findings covering a broad range of topics related to HPV research, cancer screening prevention and management of patients with HPV-associated diseases. Each presentation should not exceed 8 minutes.

Monday, May 9

PLENARY SESSION

8:00 – 9:30 PS1- Cervical cancer screening – role of molecular testing

Chair: T. Cox, C. Meijer

- | | | |
|---|------------|--------|
| • Optimal screening intervals | T. Cox | USA |
| • Screening strategies for women 30 years and older | J. Dillner | Sweden |
| • Current knowledge on screening of women less than 30 | P. Sasieni | UK |
| • Management of cytonegative / HPV positive women | P. Castle | USA |
| • Exiting women from screening | W. Kinney | USA |
| • Cervical cancer screening as a post-vaccination surveillance activity | E. Franco | Canada |

Monday, May 9

PLENARY SESSION

9:30 – 11:00 PS2 - HPV vaccination – current knowledge and the road to the future

Chair: J. Schiller, M. Stanley

- | | | |
|--|------------|----|
| • Vaccine benefits following sexual debut (catch-up/adult) | M. Stanley | UK |
|--|------------|----|

- New evidence for vaccination of males A. Giuliano USA
 - Real life impact of HPV vaccine at population level
 - The UK experience D. Salisbury UK
 - The Australian experience J. Brotherton Australia
 - Long-term follow-up: the Nordic experience (bivalent vaccine) M. Lehtinen Finland
 - An evaluation of the long-term effectiveness, immunogenicity and safety of the quadrivalent vaccine in previously vaccinated women S. Kjaer Denmark
 - HPV vaccination efficacy with less than 3 doses A. Kreimer USA
-

Monday, May 9

MAIN SCIENTIFIC SESSION

14:00 –
15:30

MSS1 - Penile HPV related diseases revisited

Chair: C. Lacey, A. Giuliano

- The burden of HPV associated penile cancer K. d'Hauwers The Netherlands
- Current knowledge on epidemiology and natural history C. Munk Denmark
- Male sexual behaviour – a risk factor for cervical cancer? X. Bosch Spain
- The global spectrum of HPV related diseases in males C. Lacey UK
- Management of penile HPV associated lesions G. Gross Germany
- HPV vaccination: what have we learned from the clinical trials? A. Giuliano USA
- Impact of male circumcision on women with HPV genital disease P. Gravitt USA

Monday, May 9

MAIN SCIENTIFIC SESSION

15:30 –
17:00

MSS2 - Anal HPV associated diseases and cancer: state of the art

Chair: J. Palefsky, N. Wentzensen

- The burden of the diseases and natural history C. Munk Denmark

- Factors influencing HPV dysplasia and anal cancer following HPV infection N. Wentzensen USA
- Diagnostic methods and clinical features S. Goldstone USA
- Who should be screened?
Is screening an effective tool? L. Abramowitz France
- Current management of AIN3 and cancer S. Goldstone USA
- Quadrivalent HPV vaccine efficacy against high-grade anal intraepithelial neoplasia in men having sex with men J. Palefsky USA

Monday, May 9

CONCURRENT SCIENTIFIC SESSION

14:00 – **SS1 – New generation of HPV assays for clinical practice**
15:30

Chair: J. Cuzick, A. Pista

Monday, May 9

CONCURRENT SCIENTIFIC SESSION

15:30 – **SS2 - The value of HPV genotyping**
17:00

Chair: P. Gravitt, C. Clavel

Monday, May 9

CONCURRENT SCIENTIFIC SESSION

14:00 – **SS3 - Vaccines 1 – Current knowledge of HPV vaccine impact**
15:30

Chair: C. de Oliveira, M. Steben

Monday, May 9

CONCURRENT SCIENTIFIC SESSION

15:30 – **SS4 - Vaccines 2 – HPV vaccine programs and monitoring: current status and lessons learned**
17:00

Chair: S. Garland, D. Pereira da Silva

Monday, May 9

CONCURRENT SCIENTIFIC SESSION

14:00 – **SS5 - Vulvar neoplasia, cancer and mimics: what the clinicians should know**
15:30

Chair: J. Bornstein, J. Martinez de Oliveira

Monday, May 9

CONCURRENT SCIENTIFIC SESSION

15:30 – **SS6 - New developments in cytopathology**
17:00

Chair: A. Herbert, C. Lopes

Tuesday, May 10

PLENARY SESSION

8:00 – 9:30 **PS3 - Can we target the adult population at high risk of cervical cancer? Consequences on screening, management and vaccination**

Chair: E. Franco, N. Broutet

- The risk heterogeneity of high-grade CIN N. Wentzensen USA
- Assessing inequalities over the world (access, resources, education) and potential solutions N. Broutet Switzerland
- Epidemiologic, genetic, behavioural factors and the male partner influence: are they important? E. Franco Canada
- Significance of molecular testing/markers and age of exposure to HPV P. Castle USA
- Specific populations at high risk of cervical cancer: should screening and vaccination be different? T. Cox USA
- Integrating and implementing screening and vaccination programs for high risk populations L. Denny South Africa

Tuesday, May 10

PLENARY SESSION

9:30 – 11:00 **PS4 - Head and neck HPV associated cancer – state of the art**

Chair: M. Gillison, S. Syrjänen

- Virological approach – meta-analysis data S. Syrjänen Finland
- Oral HPV infection and head and neck cancer risk A. Kreimer USA
- Evidence of causal association between HPV and head and neck cancer M. Gillison USA
- Molecular diagnostic methods and prognostic markers utility P. Gravitt USA
- Tumor HPV status management and survival H. Mehanna France
- The potential impact of HPV vaccines S. Kjaer Denmark

Tuesday, May 10

MAIN SCIENTIFIC SESSION

14:15 - 15:15 **MSS3 - New professional guidelines on screening and vaccination**

Chair: T. Wright, M. Arbyn

- USA T. Wright USA
- Europe M. Arbyn Belgium
- FIGO S. Pecorelli Italy
- WHO N. Broutet Switzerland
- Providers and practices M. Saraiya USA
- Panel discussion: do we need to update the current recommendations?

Tuesday, May 10

MAIN SCIENTIFIC SESSION

15:15 -
16:15

MSS4 - HPV screening: current programs and implementation procedures

Chair: L. Denny, H. Lawson

- Europe:
 - the Dutch program C. Meijer The Netherlands
 - the Italian experience G. Ronco Italy
- USA H. Lawson USA
- Developing world L. Denny South Africa

Tuesday, May 10

MAIN SCIENTIFIC SESSION

16:45 –
17:45

MSS5 - Health economics of HPV related precancers and cancers – screening and prevention: priorities and opportunities

Chair: S. Kulasingam, P. Bonanni

- The respective public health impact of screening and vaccination: what the economic models tell us S. Kulasingam USA
- What are the public health priorities in the developed world? M. Jit UK
- Adult vaccination is it cost effective? J. Bogaards The Netherlands
- Potential impact of HPV vaccination on health disparities M. Brisson Canada
- Global impact of HPV vaccination H. Berkhof The Netherlands
- Priorities in the developing world: screening vs. vaccination S. Kulasingam USA

Tuesday, May 10

8:00 – 9:30 **FC7 – Head and Neck**
Chair: A. Kreimer, T. Iftner

Tuesday May, 10

9:30 – 11:00 **FC8 – Diagnosis and Management**
Chair: E. Siegler, M. Roy

Tuesday, May 10

CONCURRENT SCIENTIFIC SESSION

14:15 – **SS7 – Best practices of colposcopy**
15:45 Chair: J. Cortes, A. Singer, J. Cardoso Moutinho

Tuesday, May 10

CONCURRENT SCIENTIFIC SESSION

16:15 – **SS8 – Contemporary management of CIN**
17:45 Chair: W. Prendiville, E. Diakomanolis

Tuesday, May 10

CONCURRENT SCIENTIFIC SESSION

14:15 – **SS9 - Vaccines 3 – From clinical trials to**
16:15 **real life settings**
Chair: J. Paavonen, B. Romanowski

Tuesday, May 10

CONCURRENT SCIENTIFIC SESSION

16:15 – 17:45 **SS10 - Screening**
Chair: G. Ronco, J. Dillner

Tuesday, May 10

CONCURRENT SCIENTIFIC SESSION

17:45 – 19:00 **SS11 - Epidemiology 1**
Age specific HPV infection and disease
Chair: S. Kjaer, J. Borrego

Tuesday, May 10

CONCURRENT SCIENTIFIC SESSION

16:15 – **SS12 - p16 in cervical and other HPV**
17:45 **related cancer**
Chair: T. Wright

Tuesday, May 10
CONCURRENT SCIENTIFIC SESSION

17:45 – **SS13 – The emerging value of molecular**
19:00 **markers**
Chair: J.P. Bogers, M. v. Knebel-Doeberitz

Tuesday, May 10
CONCURRENT SCIENTIFIC SESSION

14:15 – **SS14 - HPV and heterogeneity of head**
15:45 **and neck cancers**
Chair: M. Gillison

Tuesday, May 10
CONCURRENT SCIENTIFIC SESSION

16:15 – **SS15 – New trends on HPV testing and**
17:45 **other markers**
Chair: T. Iftner

Tuesday, May 10

14:15 15:45 **CS1 - Clinical session 1**

Chair: M. Sideri, C. Marques

- HPV testing in primary screening: should organized programs be requested before implementation?
Yes A. Anttila Finland/
No W. Kinney USA
- CIN2: to treat or not?
Yes M. Sideri Italy/ USA
No M. Stoler
- Moving from algorithms to risk based management: is it of value for the clinician?
Yes P. Castle USA/
No J. Dillner Sweden
- HPV testing: what is the preferable assay from a clinical perspective? J. Cuzick UK/USA
T. Wright
- Accuracy of colposcopy: multiple biopsies required or not?
Yes R. Pretorius USA/
No W. Prendiville Ireland

Wednesday, May 11

CONCURRENT SCIENTIFIC SESSION

8:00 – 9:30 SS16 - Recent advances and gaps in research

Chair: E. Franco, P. Castle

Wednesday, May 11

CONCURRENT SCIENTIFIC SESSION

9:30 – 11:00 SS17 - Epidemiology 2 - recent advances on epidemiology

Chair: S. De Sanjosé, M-H Mayrand

Wednesday, May 11

CONCURRENT SCIENTIFIC SESSION

11:00 – 12:30 SS18 - Vaccines 4 - New developments in HPV vaccines and drugs

Chair: L. Gissmann, P. Coursaget

Wednesday, May 11

CONCURRENT SCIENTIFIC SESSION

12:30 – 14:00 SS19 – Advanced topics on immunology and immunisation

Chair: P. Stern, B. Moscicki

Wednesday, May 11

CONCURRENT SCIENTIFIC SESSION

8:00 – 9:45 SS20 - Molecular biology and detection

Chair: M. Favre, J. Doorbar

Wednesday, May 11

CONCURRENT SCIENTIFIC SESSION

9:45 – 11:00 SS21 - HPV/HIV natural history – new insights

Chair: P. Gravitt, J. Smith

Wednesday, May 11

CONCURRENT SCIENTIFIC SESSION

11:00 – 12:30 SS22 – New insights in low resource settings

Chair: M. Kane, J. Jeronimo

Wednesday, May 11

CONCURRENT SCIENTIFIC SESSION

12:30 – 14:00 SS23 - HPV associated diseases and cancers in other tissues: what is the evidence?

Chair: T. Broker, K. Syrjänen

Wednesday, May 11

CONCURRENT SCIENTIFIC SESSION

8:00 – **SS24 - HPV testing methods: an update**
10:00 Chair: F. Carozzi, P. Snijders

Wednesday, May 11

CONCURRENT SCIENTIFIC SESSION

10:00 – **SS25 - Quality assessment of HPV testing**
12:30 Chair: H. Cubie, C. Meijer

Wednesday, May 11

CONCURRENT SCIENTIFIC SESSION

8:00 – 9:30 **SS26 – Management of cervical cancer: new strategies**
Chair: S. Dexeus, S. Pecorelli

Wednesday, May 11

9:30 – 11:00 **CS2 - Clinical session 2**
Chair: A.B. Moscicki (USA), A. Petiz (Portugal),

- Head and neck cancers: is HPV of significant interest?
Yes M. Gillison USA/
No A. Chatuverdi USA
- The best management of HPV positive women
G Ronco / Italy/
A. Anttila Finland
- Verification bias: does it matter?
Yes E. Franco Canada/
No J. Cuzick UK
- Treatment of CIN causes premature delivery
Yes M. Arbyn Belgium/
No M. Cruickshank UK
- Screening of anal cancer
Yes S. Goldstone USA/
No M. Brisson Canada

Wednesday, May 11

11:00 – **CS3 - Clinical session 3**
12:30 Chair: J. Paavonen, A. F. Jorge

- HPV vaccine for high risk populations: is it of a public health value?
Yes C. Lacey UK/
No M. Steben Canada
- HPV vaccination of males: yes or no?
Yes A. Giuliano USA/
No M. Jit UK
- Catch-up programs: are they of significant value?
Yes H. Berkhof The
No M. Arbyn Netherlands/
Belgium
- HPV vaccination for adult women: yes or no?
Yes J. Bogaards The
No H. Lawson Netherlands/
USA
- Could antibodies be considered as an indicator of efficacy
Yes P. Stern UK/
No S. Garland Australia

Wednesday, May 11

12:30 –
14:00

FC9 – HIV - HPV

Chair: L. Abramowitz, J. Smith, J. Fonseca Moutinho

SATELLITE TRAINING COURSES

Sunday, May 8

13:30 – 17:00 STC1 - Vaccinology Training Course

Chair: P. Bonanni

- All about vaccination and vaccines specificities P. Bonanni Italy
- Basics of immunology P. Stern UK
- Risks of vaccines and monitoring vaccines safety S. Garland Australia
- Detecting and assessing adverse events following immunisation: how to distinguish cause and coincidence P.L. Lopalco Sweden
- How to improve participation J. Brotherton Australia
- Implementation of vaccine programs D. Salisbury UK
- Social, ethical and communication issues V. Laurent-Ledru Belgium

Wednesday, May 11

8:00 – 12:00 **STC2 - Improving oral communication and publishing in clinical and public health research**
Chair: E. Franco, X. Bosch

"Publishing in Clinical and Public Health Research"

The objectives of this course are:

- 1) to provide an overview of principles of good scientific practice as applied to research on human subjects (emphasis on cancer research);
- 2) to discuss elements of scientific reasoning that are used in clinical and public health research and mentorship;
- 3) to discuss the process of research communication and publishing;
- 4) to discuss the key features that enhance the quality of a paper and its value to the scientific community.

Instruction will be via interactive lecture to take advantage of students' own experiences as authors; emphasis on issues pertaining to study design, ethics, data analysis, scientific integrity, and strategies of communicating and interpreting results of clinical and public health research.

This course is intended for oncologists, public health practitioners, epidemiologists, and other clinical researchers in the early stages of their careers or those who are switching from clinical or public health practice to research. Public health practitioners and policymakers may also find the contents valuable in understanding the process of scientific research and publishing. Researchers whose mother tongue is not English may find the course particularly helpful in assisting them to navigate the process of preparing, submitting, and revising manuscripts for publication in international biomedical journals.

Wednesday, May 11

8:30 – 11:30 **STC3 - Vulvar diseases course**
Chair: J. Bornstein, M. Moyal-Barracco

(separate registration required for this course)

The satellite course on vulvar disease has been designed for clinicians who currently treat or diagnose women with cervical and vaginal disease. The faculty, all past or present members of the executive council of the International Society for the Study of Vulvovaginal Disease (ISSVD), will discuss current knowledge of vulvar benign and premalignant disease, from various aspects: pathophysiology, clinical features, histological appearance, and treatment. Common and difficult cases will be presented and discussed.

- | | | |
|---|--------------|---------|
| • Introduction | J. Bornstein | Israel |
| | M. Moyal | |
| • The dermatoses | Barracco | France |
| • Benign HPV lesions: diagnosis and treatment.
Difficult cases | | |
| | M. Sideri | Italy |
| • Vulvar pain, difficult cases | J. Bornstein | Israel |
| • VIN - state of the art | E. Joura | Austria |

- Vulvar carcinoma - current treatment. difficult cases of VIN and vulvar carcinoma M. Roy Canada
- Summary and close

Wednesday, May 11

STC4 COLPOSCOPY TRAINING COURSE

8.00 - 14.00

Chair: Albert Singer (UK)

(separate registration required for this course)

This is a 6 hour intensive course conducted by 3 highly experienced colposcopists/oncologists. They will present the most up to date knowledge relating to colposcopy practise as well as of the management of cervix and lower genital tract precancer. There will be lectures as well as a very informal interactive tutorial which will be clinically orientated. Topics will range from the basic (i.e. normal cervix) to advanced (i.e. microinvasion and glandular disease). A CD (PDF form) of all PowerPoint lectures will be given out.

8.00 – 8.10	• Welcome	Faculty	
8.10 – 8.40	• The normal cervix: anatomy and functional changes	A. Singer	UK
8.40 – 9.00	• Update on the pathology of cervical precancer	A. Singer	UK
9.00 – 9.05	• Questions		
9.05 – 9.30	• How do we diagnose cervical precancer; cytology , HPV and other methods	W. Prendiville	Ireland
9.30 – 10.30	• The abnormal cervix; colposcopy and methods of examination Video case presentations	S. C. Quek	Singapore
10.30 – 10.50	• Coffee Break		
10.50 – 11.30	• Microinvasion and glandular cervical disease and other difficult colposcopic examination	S. C. Quek	Singapore
11.30 – 12.15	• Treatment of cervical precancer; who, why and how	W. Prendiville	Ireland
12.15 – 12.20	• Questions		
12.20 – 12.45	• Lower genital tract neoplasia: recognition and treatment	A. Singer	UK
12.45 – 13.55	• Case presentations ; cytology , colposcopy, pathology and treatment	A. Singer / Faculty	
13.55 – 14.00	• Summary and close		

PORTUGUESE PROGRAM

Monday 14.00 - 17.00

Portuguese Colposcopy Section - HPV Session

14,00 – 14,30 h: Conferência – Rui Medeiros; Teresa Rebelo

Human Papiloma Vírus and Cervical Câncer: A new concept in viral and phylogenetic pathology–
Rui Nobre Jorge

**14,30 – 15,50 h : Round Table –HPV Testing : Laboratory - José Alberto Moutinho;
Margarida Barros**

14,30-15,20 h: Recent methods of HPV testing in clinical practice: Advantages, limitations and
future perspectives - Conceição Saldanha

15,20-15,50 h: New molecular tests for CIN diagnosis: the future or an illusion? – Rui Medeiros

**15,50-17,00 h: Round Table – HPV testing: The clinical practice – João Saraiva; Ana
Francisca**

15,50-16,20 h: HPV tests and the cervix câncer screening – José Alberto Moutinho

16,20-17,00 h: How and when to use the HPV tests in the daily clinical practice? – Carlos Martins
Gomes

Tuesday 14.00 - 17.30

Portuguese Gynecological Cancer Section - Lower Genital Tract Pre-cancer and Cancer

14.00 – 15.30 Moderadores: Fernando Mota e Jorge Borrego

14.00-14.15 Managing cytology results: ASC-US, LSIL e AGC - José Maria Moutinho

14.15-14.30 Treating CIN 1 - Rita de Sousa

14.30-14.45 Margin lesion – what to do? Teresa Paula

14.45–15.00 CIN Follow-up - João Saraiva

15.00-15.30 Discussion

15.30 – 16.00

Coffee Break

16.00 – 17.30 Moderadores: Martinez de Oliveira e António Azinhais

16.00-16.20 Complementary means of diagnosis in vulvar disease – Is there a place for vulvoscopy? -
Martinez de Oliveira

16.20-16.40 VIN treatment and vulvar condyloma/wart - Teresa Fraga

16.40-17.00 Cervical cancer in young women - Daniel Pereira da Silva

17.00-17.30 Discussão

POSTERS

The following topics will be covered by posters:

Epidemiology

Screening

HPV testing

Molecular markers

Diagnosis & management

Programs, knowledge, awareness and education

Immunization